RNA Interference and CRISPR Technologies

RNA and CRISPR Interferences: Past, Present and Future Perspectives.- Chemical Modifications in RNA Interference and CRISPR/Cas Genome Editing Reagents.- Preparation, Determination of Activity, and Biodistribution of Cholesterol-Containing Nuclease-Resistant siRNAs In Vivo.- Multifunctional Nanodelivery Platform for Maximizing Nucleic Acids Combination Therapy.- PAMAM Dendrimers as a Delivery System for Small Interfering RNA.- Delivery of Functional Small RNAs via Extracellular Vesicles In Vitro and In Vivo.- Optimized siRNA Delivery into Primary Immune Cells using Electroporation.- Synthesis and Evaluation of Caged siRNAs with Single cRGD Modification for Photoregulating RNA Interference.- Exploring 5’-Biotinylation of the Sense Strand to Improve siRNA Specificity and Potency.- In Vivo Delivery of Cassettes Encoding Anti-HBV Primary MicroRNAs using an Ancestral Adeno-Associated Viral Vector.- Generating DNA Expression Cassettes Encoding Multimeric Artificial MicroRNA Precursors.- MiR-302-Mediated Somatic Cell Reprogramming and Method for Generating Tumor-Free iPS Cells Using miR-302.- Urinary MicroRNAs as Emerging Class of Noninvasive Biomarkers.- Improving Dendritic Cell Cancer Vaccine Potency using RNA Interference.- Unleashing the Therapeutic Potential of Dendritic and T Cell Therapies using RNA Interference.- Harnessing the Antiviral-Type Responses Induced by Immunostimulatory siRNAs for Cancer Immunotherapy.- Cancer Immunotherapy: Targeting Tumor-Associated Macrophages by Gene Silencing.- Use of RNA Interference with TCR Transfer Enhance Safety and Efficiency.- CRISPR/Cas9 Guide RNA Design Rules for Predicting Activity.- CRISPR/Cas9 Genome Editing in Human Cell Lines with DONOR Vector Made by Gibson Assembly.- Genome Editing in Zebrafish using High-Fidelity Cas9 Nucleases: Choosing the Right Nuclease for the Task.- Next Generation of Adoptive T Cell Therapy using CRISPR/Cas9 Technology: Universal or Boosted?.- Engineering T-Cells using CRISPR/Cas9 for Cancer Therapy.- CRISPR/Cas9 Mediated Genome Engineering of Primary Human B Cells.- Gene Editing in B-Lymphoma Cell Lines using CRISPR/Cas9 Technology.- Gene Knockout in Hematopoietic Stem and Progenitor Cells followed by Granulocytic Differentiation.- CRISPR/Cas9 Genome Editing of Human Induced Pluripotent Stem Cells followed by Granulocytic Differentiation.